| 1 |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
| 2 |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| 3 |
Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035[J]. Diabetes Res Clin Pract, 2014, 103(2): 137-149.
|
| 4 |
Tseng CH. Diabetes but not insulin increases the risk of lung cancer: a Taiwanese population-based study[J]. PLoS One, 2014, 9(7): e101553.
|
| 5 |
Lee JY, Jeon I, Lee JM, et al. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies[J]. Eur J Cancer, 2013, 49(10): 2411-2423.
|
| 6 |
Tseng CH. Metformin and lung cancer risk in patients with type 2 diabetes mellitus[J]. Oncotarget, 2017, 8(25): 41132-41142.
|
| 7 |
Zhu N, Zhang Y, Gong YI, et al. Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis[J]. Biomed Rep, 2015, 3(2): 235-241.
|
| 8 |
Sakoda LC, Ferrara A, Achacoso NS, et al. Metformin use and lung cancer risk in patients with diabetes[J]. Cancer Prev Res (Phila), 2015, 8(2): 174-179.
|
| 9 |
Luo J, Hendryx M, Qi L, et al. Pre-existing diabetes and lung cancer prognosis[J]. Br J Cancer, 2016, 115(1): 76-79.
|
| 10 |
Tian RH, Zhang YG, Wu Z, et al. Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis[J]. Clin Transl Oncol, 2016, 18(6): 641-649.
|
| 11 |
Cao X, Wen ZS, Wang XD, et al. The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies[J]. J Cancer, 2017, 8(13): 2532-2541.
|
| 12 |
Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions[J]. J Clin Oncol, 2005, 23(11): 2556-2568.
|
| 13 |
Lamb YN, Scott LJ. Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer[J]. Target Oncol, 2017, 12(4): 555-562.
|
| 14 |
Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib[J]. Diabetes Care, 2006, 29(7): 1711.
|
| 15 |
Brooks MB. Erlotinib appears to produce prolonged remission of insulin requiring type 2 diabetes associated with metabolic syndrome and chronic kidney disease[J]. Achieving Best Practice, 2012, 12(2): 87-90.
|
| 16 |
Brooks MB. Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases[J]. Oncologist, 2013, 18(1): e3-5.
|
| 17 |
黄 恬，蔡 稀，钟 玲. 厄洛替尼减轻STZ诱导的糖尿病肾病模型大鼠的肾损伤[J]. 中国病理生理杂志，2017, 33(8): 1460-1466.
|
| 18 |
孙 琦，王胜男，李玉秀，等. 吉非替尼对糖尿病大鼠胰岛素敏感性的影响[J]. 中华医学杂志，2009, 89(48): 3441-3443.
|
| 19 |
Prada PO, Saad MJ. Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes[J]. Expert Opin Investig Drugs, 2013, 22(6): 751-763.
|
| 20 |
杨 翠，徐 瑜，胡义德. 二甲双胍对肺腺癌耐厄洛替尼细胞株A549ER的耐药逆转作用[J/CD]. 中华肺部疾病杂志(电子版), 2014, 7(5): 507-511.
|
| 21 |
Li L, Han R, Xiao H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal[J]. Clin Cancer Res, 2014, 20(10): 2714-2726.
|
| 22 |
Morgillo F, Sasso FC, Della CCM, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines[J]. Clin Cancer Res, 2013, 19(13): 3508-3519.
|
| 23 |
Ashinuma H, Takiguchi Y, Kitazono S, et al. Antiproliferative action of metformin in human lung cancer cell lines[J]. Oncol Rep, 2012, 28(1): 8-14.
|
| 24 |
Wu N, Gu C, Gu H, et al. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153[J]. Neoplasma, 2011, 58(6): 482-490.
|
| 25 |
周寒丽，耿健雄，张 华. 二甲双胍抗肿瘤机制的研究进展[J]. 现代肿瘤医学，2015, 23(12): 1760-1763.
|
| 26 |
Li KL, Li L, Zhang P, et al. A Multicenter Double-blind Phase Ⅱ Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer[J]. Clin Lung Cancer, 2017, 18(3): 340-343.
|
| 27 |
Fasano M, Della CCM, Capuano A, et al. A multicenter, open-label phase Ⅱ study of metformin with erlotinib in second-line therapy of stage Ⅳ non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial[J]. Clin Lung Cancer, 2015, 16(1): 57-59.
|
| 28 |
Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism[J]. Nature, 2001, 414(6865): 799-806.
|
| 29 |
Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor[J]. J Biol Chem, 2002, 277(48): 46265-46272.
|
| 30 |
Ballotti R, Lammers R, Scimeca JC, et al. Intermolecular transphosphorylation between insulin receptors and EGF-insulin receptor chimerae[J]. EMBO J, 1989, 8(11): 3303-3309.
|
| 31 |
Gogg S, Smith U. Epidermal growth factor and transforming growth factor alpha mimic the effects of insulin in human fat cells and augment downstream signaling in insulin resistance[J]. J Biol Chem, 2002, 277(39): 36045-36051.
|
| 32 |
孙栋勋，蔡志毅. EGFR/PI3K/Akt细胞信号传导通路与肿瘤[J]. 检验医学，2014, 29(7): 768-773.
|
| 33 |
Kang X, Kong F, Wu X, et al. High glucose promotes tumor invasion and increases metastasis-associated protein expression in human lung epithelial cells by upregulating heme oxygenase-1 via reactive oxygen species or the TGF-β1/PI3K/Akt signaling pathway[J]. Cell Physiol Biochem, 2015, 35(3): 1008-1022.
|
| 34 |
张欣霞，陈 婷，涂 盛，等. 胰岛素信号通路与肿瘤风险相关性的研究进展[J]. 浙江中医药大学学报，2015, 39(5): 418-422.
|
| 35 |
Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis[J]. Cancer Prev Res (Phila), 2010, 3(9): 1066-1076.
|
| 36 |
Xiao Z, Gaertner S, Morresi-Hauf A, et al. Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients[J]. Neoplasia, 2017, 19(5): 385-395.
|
| 37 |
刘 喆. 胰岛素生长因子-1受体信号通路与肺癌的研究进展[J]. 中国肺癌杂志，2010, 13(6): 642-647.
|
| 38 |
Hurbin A, Wislez M, Busser B, et al. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma[J]. J Pathol, 2011, 225(1): 83-95.
|
| 39 |
Yeo CD, Kim YA, Lee HY, et al. Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells[J]. Exp Lung Res, 2017, 43(1): 29-37.
|
| 40 |
Hussmann D, Madsen AT, Jakobsen KR, et al. IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells[J]. Oncotarget, 2017, 8(20): 33300-33315.
|
| 41 |
Suda K, Mizuuchi H, Sato K, et al. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor[J]. Int J Cancer, 2014, 135(4): 1002-1006.
|
| 42 |
Li L, Gu X, Yue J, et al. Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC[J]. Oncotarget, 2017, 8(54): 92240-92253.
|
| 43 |
Langer CJ, Novello S, Park K, et al. Randomized, phase Ⅲ trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2014, 32(19): 2059-2066.
|
| 44 |
吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
| 45 |
孙晓远，刘 斌，蒋捍东，等. 不同EGFR突变位点晚期非小细胞肺癌的临床特征及对靶向药物治疗反应分析[J/CD]. 中华肺部疾病杂志(电子版), 2018, 11(3): 289-294.
|